BioSig Technologies Inc has announced that Gray Fleming will be joining the company as its chief commercial officer.
The Westport, Connecticut-based company said that Fleming will bring over 20 years of experience in the healthcare industry.
“We are pleased to welcome Gray to the team as we enter an advanced phase of targeted market release within our commercial growth strategy,” said Kenneth L. Londoner, CEO of BioSig in a statement.
READ: BioSig Technologies initiates Artificial Intelligence Development Program with Israel-based Technion
He added: “Gray’s second-to-none knowledge of electrophysiology space and his impressive track record in capturing and growing market share in all regions of our strategic geographic interest is well aligned with our mission to bring our signal processing technology to as many hospitals as possible in the coming years.”
During his 17-year-long tenure with Abbott Laboratories (NYSE:ABT) and St. Jude Medical (NYSE:STJ), Fleming held several commercial leadership positions, including Vice President of Cardiac Sales, when he led sales and customer relationship management activities in some of the most significant strategic areas of focus.
The company said that Fleming’s experience in delivering high-performing sales management initiatives led to substantial revenue growth with several key accomplishments, including the successful contracting of multiple leading IDN and GPO organizations. These initiatives resulted in some of the largest market share gains in the company’s history while also delivering substantial overhauls of historically underperforming regions throughout the Central Time Zone.
Before accepting a role at BioSig, Fleming held the position of Chief Commercial Officer at Carecubes, a company created to provide a temporary and scalable negative pressure isolation technology solution based upon original joint request from the Defense Advanced Research Projects Agency (DARPA) and Centers for Disease Control and Prevention (CDC).
“I am extremely excited to be returning to the electrophysiology arena and, most importantly, dedicating effort and energy towards supporting the fight against Atrial Fibrillation. My experience offers me the luxury of understanding that without the signal, the procedure cannot be possible,” said Fleming in a statement.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
Contact Ritika at ritika@proactiveinvestors.com